A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy of Visugromab in Combination with Pembrolizumab, Pemetrexed, and Cis- /Carboplatin in Participants with Newly Diagnosed Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Sponsor:
- CatalYm GmbH
- Sponsor Study ID:
- CTL-002-003
- CTO #:
- 104085
- NCT Number:
- NCT07098988
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- To investigate the antitumoral effect in participants treated with visugromab plus ICT versus placebo plus ICT
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Alexander, Mariam, at alexanma@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina